Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $43,900 | 31 | 60.1% |
| Food and Beverage | $17,292 | 785 | 23.7% |
| Consulting Fee | $5,500 | 2 | 7.5% |
| Travel and Lodging | $4,205 | 22 | 5.8% |
| Unspecified | $1,472 | 2 | 2.0% |
| Gift | $491.58 | 1 | 0.7% |
| Education | $142.17 | 2 | 0.2% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Allergan, Inc. | $51,781 | 139 | $0 (2022) |
| ABBVIE INC. | $5,266 | 64 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $2,324 | 76 | $0 (2023) |
| Eli Lilly and Company | $1,472 | 2 | $0 (2022) |
| Biogen, Inc. | $941.42 | 38 | $0 (2023) |
| Amgen Inc. | $898.76 | 36 | $0 (2022) |
| Sunovion Pharmaceuticals Inc. | $683.02 | 68 | $0 (2022) |
| Teva Pharmaceuticals USA, Inc. | $649.44 | 22 | $0 (2023) |
| Mallinckrodt Enterprises LLC | $648.16 | 28 | $0 (2019) |
| GENZYME CORPORATION | $552.21 | 23 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $89.00 | 5 | Celgene Corporation ($34.53) |
| 2023 | $1,285 | 40 | Novartis Pharmaceuticals Corporation ($343.46) |
| 2022 | $8,185 | 94 | ABBVIE INC. ($4,672) |
| 2021 | $13,744 | 124 | Allergan, Inc. ($11,492) |
| 2020 | $7,752 | 129 | Allergan, Inc. ($5,999) |
| 2019 | $19,100 | 152 | Allergan Inc. ($16,090) |
| 2018 | $10,673 | 139 | Allergan Inc. ($7,992) |
| 2017 | $12,174 | 162 | Allergan Inc. ($9,571) |
All Payment Transactions
845 individual payment records from CMS Open Payments — Page 1 of 34
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 07/19/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $20.80 | General |
| Category: Neuroscience | ||||||
| 04/22/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $13.73 | General |
| Category: Neuroscience | ||||||
| 03/27/2024 | Abbott Laboratories | ETERNA (Device) | Food and Beverage | In-kind items and services | $14.09 | General |
| Category: Neuromodulation | ||||||
| 02/16/2024 | Abbott Laboratories | INFINITY (Device) | Food and Beverage | In-kind items and services | $13.67 | General |
| Category: Neuromodulation | ||||||
| 01/19/2024 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $26.71 | General |
| 11/14/2023 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $11.53 | General |
| Category: Neurology | ||||||
| 08/12/2023 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $27.06 | General |
| Category: NEUROSCIENCE | ||||||
| 07/10/2023 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $20.27 | General |
| Category: NEUROSCIENCE | ||||||
| 06/30/2023 | ABBVIE INC. | DUOPA (Drug) | Food and Beverage | In-kind items and services | $22.97 | General |
| Category: NEUROSCIENCE | ||||||
| 06/14/2023 | Lilly USA, LLC | EMGALITY (Drug), REYVOW | Food and Beverage | In-kind items and services | $13.53 | General |
| Category: Neuroscience | ||||||
| 06/13/2023 | Horizon Therapeutics plc | UPLIZNA (Drug) | Food and Beverage | In-kind items and services | $77.10 | General |
| Category: UPLIZNA | ||||||
| 06/09/2023 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $22.82 | General |
| Category: NEUROSCIENCE | ||||||
| 05/30/2023 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $11.10 | General |
| Category: NEUROSCIENCE | ||||||
| 05/24/2023 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $117.20 | General |
| Category: NEUROSCIENCE | ||||||
| 05/24/2023 | Horizon Therapeutics plc | UPLIZNA (Drug) | Food and Beverage | In-kind items and services | $14.50 | General |
| Category: UPLIZNA | ||||||
| 05/23/2023 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $6.50 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 05/20/2023 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $20.21 | General |
| Category: NEUROSCIENCE | ||||||
| 05/10/2023 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $10.27 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 05/01/2023 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Immunology | ||||||
| 04/27/2023 | Nevro Corp. | Senza (Device) | Food and Beverage | In-kind items and services | $17.85 | General |
| Category: Spinal Cord Stimulator | ||||||
| 04/20/2023 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $12.99 | General |
| 04/19/2023 | Biogen, Inc. | VUMERITY (Drug) | Food and Beverage | In-kind items and services | $19.43 | General |
| Category: Neurology | ||||||
| 04/06/2023 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $18.23 | General |
| Category: Neurology | ||||||
| 04/05/2023 | BANNER LIFE SCIENCES, LLC | BAFIERTAM (Drug) | Food and Beverage | In-kind items and services | $16.89 | General |
| Category: Immune | ||||||
| 03/25/2023 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $25.07 | General |
| Category: BOTOX THERAPEUTIC | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 4, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GALCANEZUMAB VERSUS RIMEGEPANT IN ADULT PARTICIPANTS WITH EPISODIC MIGRAINE | Eli Lilly and Company | $1,472 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 61 | 6,738 | 172,027 | $3.5M | $2.0M |
| 2022 | 61 | 7,733 | 145,787 | $4.2M | $2.4M |
| 2021 | 52 | 5,000 | 107,159 | $2.3M | $1.4M |
| 2020 | 53 | 4,358 | 84,940 | $1.9M | $1.0M |
All Medicare Procedures & Services
227 procedure records from CMS Medicare Utilization — Page 1 of 10
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2023 | 245 | 147,947 | $1.2M | $717,300 | 60.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 1,204 | 4,539 | $862,410 | $569,353 | 66.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 838 | 1,779 | $249,060 | $159,594 | 64.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 578 | 578 | $156,060 | $85,275 | 54.6% |
| 64646 | Injection of chemical for paralysis of nerve muscles on trunk, 1-5 muscles | Office | 2023 | 208 | 643 | $125,385 | $72,288 | 57.7% |
| 64615 | Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | Office | 2023 | 222 | 683 | $129,770 | $43,011 | 33.1% |
| 90837 | Psychotherapy, 1 hour | Office | 2023 | 62 | 322 | $56,350 | $33,116 | 58.8% |
| 64450 | Injection of anesthetic agent and/or steroid into other nerve or branch | Office | 2023 | 80 | 370 | $58,800 | $25,268 | 43.0% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 92 | 520 | $49,400 | $23,346 | 47.3% |
| 98929 | Osteopathic manipulative treatment, 9-10 body regions | Office | 2023 | 29 | 391 | $44,965 | $22,965 | 51.1% |
| 97112 | Therapy procedure to re-educate brain-to-nerve-to-muscle function, each 15 minutes | Office | 2023 | 29 | 925 | $41,625 | $18,209 | 43.7% |
| 95886 | Needle measurement of electrical activity in arm or leg muscles, complete study | Office | 2023 | 178 | 223 | $26,880 | $16,632 | 61.9% |
| 96116 | Exam of neurobehavioral status, first hour | Office | 2023 | 176 | 223 | $27,875 | $15,836 | 56.8% |
| 95913 | Nerve conduction, 13 or more studies | Office | 2023 | 71 | 75 | $29,250 | $14,936 | 51.1% |
| 95911 | Nerve conduction, 9-10 studies | Office | 2023 | 78 | 85 | $26,350 | $14,000 | 53.1% |
| 96132 | Evaluation of neuropsychological test, first hour | Office | 2023 | 135 | 138 | $24,150 | $13,556 | 56.1% |
| 96374 | Injection of drug or substance into vein | Office | 2023 | 89 | 475 | $35,625 | $13,403 | 37.6% |
| 96125 | Test to assess the ability to complete specific functional tasks applicable to environment | Office | 2023 | 83 | 165 | $23,100 | $13,139 | 56.9% |
| 64400 | Injection of anesthetic agent and/or steroid into face nerve | Office | 2023 | 28 | 118 | $25,170 | $11,126 | 44.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 124 | 160 | $15,200 | $9,357 | 61.6% |
| 20553 | Injection of trigger points, 3 or more muscles | Office | 2023 | 77 | 330 | $28,050 | $8,769 | 31.3% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 167 | 189 | $11,340 | $8,027 | 70.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 62 | 62 | $13,330 | $7,147 | 53.6% |
| 96366 | Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | Office | 2023 | 56 | 463 | $13,890 | $7,125 | 51.3% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 66 | 660 | $19,800 | $6,813 | 34.4% |
About Dr. Stuart Hetrick, D.O
Dr. Stuart Hetrick, D.O is a Neurology healthcare provider based in Phoenix, Arizona. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/11/2005. The National Provider Identifier (NPI) number assigned to this provider is 1932101730.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Stuart Hetrick, D.O has received a total of $73,003 in payments from pharmaceutical and medical device companies, with $89.00 received in 2024. These payments were reported across 845 transactions from 79 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($43,900).
As a Medicare-enrolled provider, Hetrick has provided services to 23,829 Medicare beneficiaries, totaling 509,913 services with total Medicare billing of $6.9M. Data is available for 4 years (2020–2023), covering 227 distinct procedure/service records.
Practice Information
- Specialty Neurology
- Location Phoenix, AZ
- Active Since 08/11/2005
- Last Updated 03/31/2021
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1932101730
Products in Payments
- BOTOX (Biological) $28,988
- BOTOX (Drug) $15,990
- BOTOX CHRONIC MIGRAINE (Drug) $6,267
- UBRELVY (Drug) $5,414
- Aimovig (Biological) $885.79
- KESIMPTA (Drug) $814.84
- AIMOVIG (Biological) $794.23
- ACTHAR (Biological) $714.90
- APTIOM (Drug) $662.17
- OCREVUS (Biological) $515.03
- GILENYA (Drug) $511.73
- Humphrey HFA (Device) $491.58
- TYSABRI (Biological) $329.52
- SOLIRIS (Drug) $317.81
- AUBAGIO (Drug) $294.76
- Briviact (Drug) $284.12
- VYEPTI (Biological) $259.60
- Nalocet (Drug) $246.48
- ZEPOSIA (Drug) $232.66
- LEMTRADA (Drug) $228.02
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Phoenix
Barry Hendin, Md, MD
Neurology — Payments: $3.0M
Maria Ospina, Md, MD
Neurology — Payments: $1.7M
Dr. Suraj Muley, Md, MD
Neurology — Payments: $1.5M
Steve Chung, M.d, M.D
Neurology — Payments: $993,222
Shafeeq Ladha, M.d, M.D
Neurology — Payments: $712,796
Lori Travis, Md, MD
Neurology — Payments: $705,788